NCT04643366View on ClinicalTrials.gov

Total Neoadjuvant Therapy With mFOLFOX and Short-course Radiation in Resectable Rectal Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

54

Participants

Timeline

Start Date

January 28, 2021

Primary Completion Date

January 31, 2028

Study Completion Date

January 31, 2033

Conditions
Rectal Cancer
Interventions
DRUG

Chemotherapy

Neoadjuvant chemotherapy with 2 months of combination oxaliplatin and 5-Fluorouracil, leucovorin, and oxaliplatin (mFOLFOX)

RADIATION

Radiation Therapy

Pelvic Intensity-modulated radiation therapy (IMRT)

Trial Locations (3)

23230

RECRUITING

Virginia Cancer Institute, Richmond

23298

RECRUITING

Virginia Commonwealth University Massey Cancer Center, Richmond

23970

RECRUITING

VCU Community Memorial Healthcenter, South Hill

All Listed Sponsors
lead

Virginia Commonwealth University

OTHER